A Tumor-stroma Targeted Oncolytic Adenovirus Replicated in Human Ovary Cancer Samples and Inhibited Growth of Disseminated Solid Tumors in Mice

M Veronica Lopez¹, Angel A Rivera², Diego L Viale¹, Lorena Benedetti¹, Nicasio Cuneo³, Kristopher J Kimball⁴, Minghui Wang², Joanne T Douglas², Zeng B Zhu², Alicia I Bravo⁵, Manuel Gidekel⁶, Ronald D Alvarez⁴, David T Curiel²,⁷ and Osvaldo L Podhajcer¹

¹Laboratory of Molecular and Cellular Therapy, Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina; ²Division of Human Gene Therapy, Department of Medicine, Obstetrics and Gynecology, Pathology and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama, USA; ³Hospital Municipal de oncología Marie Curie, Servicio de Ginecología-Departamento de Cirugía, Buenos Aires, Argentina; ⁴The Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, Alabama, USA; ⁵Molecular Immunopathology Section, Hospital Eva Perón, Buenos Aires, Argentina; ⁶Universidad de la Frontera, Temuco, Chile; ⁷Biologic Therapeutics Center, Division of Cancer Biology, Department of Radiation Oncology at Washington University School of Medicine, St Louis, Missouri, USA

Targeting the tumor stroma in addition to the malignant cell compartment is of paramount importance to achieve complete tumor regression. In this work, we modified a previously designed tumor stroma-targeted conditionally replicative adenovirus (CRAd) based on the SPARC promoter by introducing a mutated E1A unable to bind pRB and pseudotyped with a chimeric Ad5/3 fiber (Ad F512v1), and assessed its replication/lytic capacity in ovary cancer in vitro and in vivo. AdF512v1 was able to replicate in fresh samples obtained from patients: (i) with primary human ovary cancer; (ii) that underwent neoadjuvant treatment; (iii) with metastatic disease. In addition, we show that four intraperitoneal (i.p.) injections of 5 x 10¹⁰ v.p. eliminated 50% of xenografted human ovary tumors disseminated in nude mice. Moreover, AdF512v1 replication in tumor models was enhanced 15–40-fold when the tumor contained a mix of malignant and SPARC-expressing stromal cells (fibroblasts and endothelial cells). Contrary to the wild-type virus, AdF512v1 was unable to replicate in normal human ovary samples while the wild-type virus can replicate. This study provides evidence on the lytic capacity of this CRAd and highlights the importance of targeting the stromal tissue in addition to the malignant cell compartment to achieve tumor regression.

Received 23 November 2011; accepted 22 June 2012; advance online publication 4 September 2012. doi:10.1038/mt.2012.147

INTRODUCTION

Ovarian cancer is one of the leading gynecologic malignancies globally; Scandinavia, Israel, and North America have the highest rates of incidence (10–15/100,000) while developing countries and Japan exhibit the lowest incidence (5/100,000).¹⁻² Although progress in conventional therapies (surgery, chemotherapy, and irradiation) has been achieved, the 5-year survival rate for patients with advanced stage ovarian cancer is still low.³

One of the potential approaches to tackle the advanced stages of the disease is the use of conditionally replicative adenoviruses (CRAds).⁴ Several oncolytic adenoviruses, including few CRAds, were assessed in ovary cancer models following grafting of human cells in immunodeficient mice.⁵⁻⁷ Different CRAds whose replication was driven by the promoters corresponding to VEGF⁵, Cox-2,⁶ the leukoprotease inhibitor,⁷ CXCR4, Survivin, and Mesothelin⁸ also exhibited important therapeutic efficacy on disseminated ovarian cancer models and extended mice survival, but none of them was reported to be able to eliminate disseminated tumors.⁵⁻⁷ In all cases, the target of the viruses was the malignant epithelium with no specific consideration on the capacity of the viruses to target the stromal cell compartment. The nonreplicative adenovirus Ad5.SSTR/TK.RGD where gene expression is driven by an immediate-early CMV promoter,⁹ the E1B-55kd gene deleted oncolytic adenovirus ONYX-015 with no specificity for ovarian cancer,¹¹ and the CRAd Ad5-Δ24RGD,¹² entered clinical trials. Despite the lack of partial or complete responses the trials highlighted the feasibility and safety of oncolytic adenoviruses use in the clinics, and reinforced the need to enhance viral replication and specificity.

Recent studies have shown that most aggressive ovarian cancer, especially those disseminated in the peritoneum and the omentum, exhibited a high content of genes expressed by stromal cells.¹³ Stringent follow up studies demonstrated that patients with tumors showing enhanced activity of stromal genes exhibited the poorest survival.¹³ Type I and III collagen produced by the tumor

Correspondence: M Veronica Lopez, Laboratory of Molecular and Cellular Therapy, Instituto Leloir, IIBBA-CONICET, Avenida Patricia Argentina 435, (CT405BWE), Buenos Aires, Argentina. E-mail: mlopez@leloir.org.ar (or) Osvaldo L Podhajcer, Fundación Instituto Leloir, Av. Patricia Argentina 435, (CT405BWE) Buenos Aires, Argentina. E-mail: opodhajcer@leloir.org.ar

Molecular Therapy
stroma were proposed as predictors of poor outcome in human ovarian cancer.²¹ Thus, novel approaches based on medicines that target the tumor stroma compartment can be highly effective in elusive tumors such as advanced ovarian cancer.

SPARC (secreted protein, acidic, rich in cysteine) is a secreted glycoprotein that has been associated with most aggressive human cancers.²²–²⁵ Elevated immunostaining was observed in 40–80% of human malignant ovarian carcinomas.²⁶–²⁸ Interestingly, SPARC was mainly expressed in the tumor stroma, including endothelial cells and fibroblasts, in close contact with the leading edge of the tumor; in addition, almost 15% of ovary carcinomas exhibited SPARC expression in epithelial cells.²² However, in situ hybridization showed no SPARC reactivity in malignant ovary epithelial cells suggesting that in most cases SPARC is secreted by stromal fibroblasts and internalized by epithelial cells at the tumor-stromal interface.²⁰ It appears that SPARC expression is downregulated in several types of epithelial cancer cells due to promoter methylation.²¹

With the aim of targeting the stromal compartment of the tumor mass, we have previously designed a CRAd based on a specific fragment of the SPARC promoter (Ad-F512). Ad-F512 was also active on pancreatic cancer cells with silenced SPARC expression due to promoter methylation; however, Ad-F512 efficacy was greatly dependent on the presence of the accompanying stromal cells both in xenografted human melanoma and pancreatic cancer models.²² Here, we demonstrate a strong therapeutic effect of an improved version of Ad-F512 (named AdF512v1), where the F512-SPARC promoter drives the expression of E1A mutated in one of the pRb-binding sites, and the CRAd was pseudotyped with a chimeric fiber Ad5/3. We show that AdF512v1 replicated in fresh tissue explants obtained from ovarian cancer patients that received or not neoadjuvant chemotherapy and in disseminated tumors, but exhibited no replication in nonmalignant human ovary tissue explants; AdF512v1 was also therapeutically effective in a human ovarian cancer model disseminated in the peritoneum and cured 50% of the mice. Moreover, AdF512v1 showed enhanced replication in vitro in ovary cancer xenografts that contained human stromal cells holding promise regarding its potential utility in solid desmoplastic tumors.

RESULTS

In vitro activity of different versions of Ad-F512 on ovary cancer cell lines

In previous studies, we observed that Ad-F512 was active both in human melanoma cells and certain pancreatic cancer cells lines regardless of SPARC mRNA levels.²² In order to assess whether the F512-SPARC promoter is active in epithelial ovary cancer cells we transduced three ovary cancer cell lines with nonreplicative adenoviral vectors pseudotyped or not with the chimeric fiber 5/3 and expressing luciferase under the control of F512-SPARC. These studies confirmed that F512-SPARC was active in ovary cancer cells regardless of SPARC mRNA levels (Figure 1a and Supplementary Table S1). Moreover, F512-SPARC was as active as the SV40 promoter and the viral vector carrying the chimeric fiber 5/3 showed 2 to almost 80-fold—enhanced activity compared to the viral vector carrying the native type 5 fiber (Figure 1a).

Therefore, we decided to construct four novel versions of Ad-F512 pseudotyped with the chimeric fiber 5/3 and carrying different variants of mutated E1A that can restrict viral replication in nonmalignant tissue. AdF512v1 includes a deletion that restricts E1A binding to pRb; AdF512v2 includes an E1A deletion that restricts its binding to p300 and AdF512v3 includes E1A mutated both in the pRb- and p300-binding sites; AdF512wt contains the E1A wild type (Figure 1b). By reverse transcription-PCR analysis we observed that AdF512v1 and AdF512wt exhibited quite similar patterns of E1A RNA expression with the presence of five bands of different molecular weights; part of these bands were absent in AdF512v2 and AdF512v3 (Figure 1c); in coincidence with the mRNA pattern, AdF512v1 and AdF512wt showed very similar E1A protein pattern, while AdF512v2 and the double mutant exhibited lower or faint levels respectively, of the highest molecular weight E1A band and the appearance of E1A bands of lower molecular weights (Figure 1d).

Based on the differences in E1A expression pattern at the mRNA and protein level between the different CRAds we decided to compare their lytic capacity in four different ovary cancer cell lines. AdF512v1 exhibited the best lytic effect in all the cell lines assayed (Figure 2a–d). The percentage of remaining viable cells after infection with AdF512v1 (at multiplicity of infection (MOI) 100) was 25, 8, 12, and 7% for OV-4, SKOV3.ip1, OVCAR-3, and PA-1 ovary cancer cells, respectively. At the lowest MOIs (0.1–10), Ad-wt 5/3 was slightly more effective than AdF512v1 OV-4, OVCAR-3, and SKOV3.ip1 and more effective in PA-1 cells although at MOI 100 both viruses exhibited a similar lytic effect. In order to confirm the lytic capacity of AdF512v1, we transduced three of the ovary cancer cell lines with AdF512v1 at MOI 100. We observed by flow cytometry analysis the absence of viable cells 4 days after infection confirming the lytic capacity of AdF512v1 on ovary cancer cells (Supplementary Figure S1). Ad-wt 5/3 was used as a control of cell lysis.

Ex vivo replication of AdF512v1 in fresh human ovary cancer explants

Instead of pursuing the comparison of the different CRAds only in terms of their in vitro lytic capacity on malignant cell lines, we decided to further explore their capacity to replicate ex vivo on freshly available tumor explants. The use of these explants is becoming a valuable tool to assess viral replication since they resemble the situation CRAds face in the clinics. The explants used in the present studies exhibited epithelial cells nests intermingled in abundant stroma containing mainly fibroblasts and some endothelial vessels that exhibited intense SPARC staining (Supplementary Figure S2a). Freshly available explants were obtained from patients undergoing surgery due to a primary or metastatic ovarian carcinoma; normal ovary samples were obtained from patients undergoing surgery for other pathologies and expressed faint levels of SPARC (Supplementary Figure S2b). Initial samples transduced with the nonreplicative Ad-F512(Luc 5/3) confirmed that F512-SPARC was at least 10-times more active in the ovary cancer explants than in normal ovaries (Supplementary Figure S2c). CRAds replication was evaluated in explants obtained from 13 patients. Samples were infected at ~500 v.p./cell of the different Ad-F512 versions, and compared to Ad-wt 5/3. In preliminary studies we determined that the best time for E4 assessment as a surrogate marker of viral replication is 72 hours after infection (data not shown). We analyzed samples from 4 primary tumors obtained from untreated patients, 5...
primary tumors from 4 patients with previous chemotherapy, 4 metastatic samples obtained from 2 patients and 5 normal ovary samples. AdF512v1 was the only CRAd that replicated in ovary cancer samples 7, 10, and 13 (Figure 3a, c and d). Interestingly, AdF512v1, that we confirmed was unable to bind pRb (Supplementary Figure S3), did not replicate in normal ovary explants obtained from postmenopausal patients 5, 11, 12, 13, and 17 (Figures 3d and 4).

Interestingly, none of the novel CRAds-containing mutated E1A was able to replicate in the malignant explants (Figure 3).

In further studies, we were able to evaluate AdF512v1 replication in samples from patients that ended paclitaxel and carboplatin neoadjuvant chemotherapy 1 month before surgery (samples 14, 15, 16, and 19, Figure 5); in two cases (samples 15 and 16) we also included disseminated tumor tissue obtained from different
regions of the peritoneal cavity and in case 14 we also obtained a sample from a nonmalignant ovary (Figure 5). AdF512v1 significantly replicated in malignant samples obtained from intestine and liver metastasis indicating that remnant cells after neoadjuvant chemotherapy are sensitive to the CRAd lytic activity (Figure 5). Histological analyses confirmed that remnant malignant cells were viable with no evidence of necrotic cells (data not shown). With the exception of cancer sample 14 and normal sample 17, Ad-wt 5/3 could replicate in all samples regardless of whether they were cancer or noncancer ovary tissue (Figures 3–5). Interestingly, the replication rates of AdF512v1 were superior to Ad-wt 5/3 in cancer samples 7, 10, and 19; Ad-wt 5/3 replication increased sixfold at 72 hours in patient 7, whereas AdF512v1 replication increased 100-fold at the same time point. In patient 10, we observed sixfold increase with Ad-wt 5/3 and 46-fold increased replication with AdF512v1, while in patient 19 was 40 and 714, respectively (Figures 3a,c and 5d, and Supplementary Table S2). Mostly important, with the exception of a slight replication in sample 18, AdF512v1 was essentially unable to replicate in normal ovary tissue. Thus, the overall ex vivo data with human samples prompted us to select AdF512v1 to further in vivo studies in animal models of disseminated solid human ovary cancer.

In vivo studies with AdF512v1

Therapeutic efficacy on a disseminated xenograft model. To further assess the in vivo therapeutic efficacy of AdF512v1 we injected $3 \times 10^6$ luciferase-expressing SKOV3-luc ovary cancer cells in female nude mice peritoneum. Carcinomatosis developed in 6 days when visible tumors were observed. Treatment was initiated the next day by administering 4 injections intraperitoneal (i.p.) of $5 \times 10^{10}$ v.p./400 μl of virus or control vehicle every other day (Figure 6a). Tumor growth was evaluated in two independent experiments by bioluminescent imaging follow up at days 9, 23, and 30 after the initiation of AdF512v1 administration (Figure 6b and c). In one experiment, we also included the parental CRAd Ad-F512 as an additional control. By day 30 mice were sacrificed and the number and weight of metastases was determined. We observed a strong increase in the luminescence signal in control and Ad-F512-treated animals whereas in mice treated with AdF512v1 the signal intensity was strongly inhibited (Figure 6b and c). In fact, we were unable to detect luminescence signal in 1/5 (first experiment) and 3/6 (second experiment) AdF512v1-treated mice indicating tumor absence. Macroscopic and microscopic examination of the peritoneal cavity at autopsy revealed no evidence of viable tumor tissue in cured mice while control mice
showed areas of luminescence emission confirmed as micrometastases in spleen, diaphragm and pancreas (Supplementary Figure S4a). Quantification of visible metastases revealed an average of 4 metastatic foci in control mice, 3 metastatic foci in Ad-F512-treated mice while mice treated with AdF512v1 showed none or a maximum of 1 metastatic nodule per mice in both experiments (Supplementary Figures S4b and c). Similar differences between AdF512v1-treated and control or Ad-F512-treated mice were observed when the weight of the metastatic mass was compared (Supplementary Figures S4d and e). Although, AdF512v1 was not designed for systemic use we established its efficacy on this model of disseminated cancer after intravenous administration through the tail vein. No therapeutic effect was observed with a single administration of $10^{10}$ v.p. of AdF512v1 administered 7 days after SKOV3-luc ovary cancer cells injection (Supplementary Figure S5a). In a second experiment mice were administered twice with the CRAds with 1 week difference, and despite the fact that we have not seen statistical differences (Supplementary Figure S5b), 1/5 mice treated with AdF512v1 exhibited a visible reduction in the tumor mass (Supplementary Figure S5c).**

**Viral retention in the tumor niche**

Based on the previous in vivo data, our next aim was to establish whether differential CRAd retention at the tumor niche was associated with the in vivo therapeutic effect. Initially, we injected i.p. $5 \times 10^{10}$ v.p. of Ad-F512(Luc-5/3) in healthy mice and 48 hours later we observed considerable luciferase activity restricted mainly to the liver and to a lesser extent to the spleen and gonads (Figure 7a). The other organs showed negligible luciferase expression. Next, we grafted mice with SKOV3-luc ovary cancer cells followed by AdF512v1 administration once i.p. at day 7 and removed tumor, liver, and spleen 5 hours, 1, 3, 4, and 18 days post-AdF512v1 injection to establish viral retention by the different organs; gonads were discarded in this initial experiment due to the presence of infiltrating malignant cells that were detected own to the routine luminescence analysis performed to avoid contamination by infiltrating malignant cells. We observed that the tumor mass was very efficiently infected since there were $10$–$16$ more AdF512v1 particles in tumor samples at 5 hours and at day 1 compared to liver and spleen (Figure 7b). In addition, no viral particles were retained in liver and spleen by day 18 whereas the tumor showed the presence of almost $500$ E4 copies per ng of DNA (Figure 7b). In a second experiment viral particles were evaluated at days 1 and 18 and once more we observed that AdF512v1 retention by the tumor was very high compared to the normal organs (Figure 7c). Interestingly, AdF512v1 levels in tumor-infiltrated gonads at 18 days was 250-fold higher than the levels in tumor-free gonads indicating that the virus targets and is retained preferentially by the tumor niche (Figure 7c).
Ex vivo and in vivo effect of AdF512v1 on tumors composed of malignant and stromal cells

The previous data demonstrated that AdF512v1 is a more potent version of Ad-F512 that was designed to target both the malignant and the stromal compartment of the tumor mass. Human adenoviruses such as AdF512v1 do not replicate in murine stromal cells that are recruited to the growing human ovary tumor xenograft. Therefore, we performed a series of experiments to establish the...
Figure 6 AdF512v1 treatment of mice-harboring intraperitoneally disseminated ovary cancer. (a) Protocol followed in the in vivo assays (b, c) evaluation of the antitumor effect of AdF512v1, Ad-F512 or vehicle [phosphate-buffered saline (PBS)] quantified as photons per experimental time point in two independent experiments. Error bars represent the mean ± SEM. Number of mice in (b): AdF512v1 (n = 5), Ad-F512 (n = 5), and PBS (n = 4); in (c): AdF512v1 (n = 6), and PBS (n = 5). P < 0.05, and **P < 0.01.

Figure 7 AdF512v1 retention at different organs. (a) Naive mice were intraperitoneal (i.p.) injected once with Ad-F512 (Luc 5/3) and 48 hours later the main organs were collected and luciferase activity was assayed. Results are presented as relative light units (RLU) normalized for total protein concentration. (b) Mice-harboring tumors disseminated in the peritoneum were i.p. injected with AdF512v1 and after 5 hours and 1, 3, 4, and 18 days, two to three mice were sacrificed and DNA was extracted to assess E4 levels. Data is expressed as E4 copy number per nanogram of DNA. (c) E4 levels were assessed at days 1 and 18 postinfection. Error bars represent the mean ± SEM, where n = 2 or 3.
relevance of the stromal cell component on AdF512v1 therapeutic efficacy. In initial experiments we observed that human fetal fibroblasts WI-38 that exhibit characteristics that resemble cancer-associated fibroblasts, and transformed-microendothelial cells (HMEC-1) could support replication of AdF512v1 that can lyse these type of stromal cells (Supplementary Figure S6). In a second series of experiments we plated (ratio 1:1:1) a mix of SKOV3-luc ovary cancer cells, WI-38 fibroblasts and HMEC-1 transformed-microendothelial cells previously infected or not with AdF512v1 and evaluated total cell viability with MTS and viable SKOV3-luc cells through luciferase expression. The strongest in vitro lytic effect (both by MTS and luciferase expression) was observed when the three cell types were previously infected with AdF512v1 (Figure 8a and Supplementary Table S3 and Supplementary Figure S7). Moreover, previous infection of stromal cells, once at a time, with AdF512v1, led to significant reduction in the amount of remaining viable cells and to almost the complete elimination of SKOV3-luc cells, suggesting that stromal cells supported viral replication and spreading that led to the elimination of coplated ovary cancer cells (Figure 8a and Supplementary Table S3).

To further assess the involvement of the stromal compartment in viral efficacy, we established SKOV3-luc subcutaneous tumors in nude mice combined or not with a mix of HMEC-1 and WI-38 cells. When tumors reached 500 mm³ animals were sacrificed and tumor explants were ex vivo treated and infected as described for human tumor samples. We observed that mixed tumors containing ovary cancer and stromal cells were infected with less efficiency than tumors without stromal cells (see E4 copy number levels at 5 hours postinfection, Figure 8b). Ad-wt 5/3 replication at 72 hours was marginally affected by the presence of stromal cells (Figure 8b). Interestingly, AdF512v1 showed increased rates of replication in tumors containing stromal cells clearly suggesting that stromal cells can enhance viral replication leading to increased lytic activity (Figure 8b). Interestingly, similar experiments performed with another ovary cancer cell line PA-1 that express SPARC but was less sensitive to AdF512v1 lytic effect than SKOV3 cells, also showed an improvement in viral replication in the presence of stromal cells (Supplementary Figure S8). In fact both Ad-wt 5/3 and AdF512v1 were unable to replicate in tumors made of cancer cells alone (Supplementary Figure S8) indicating that stromal cells play a relevant role probably by supporting viral replication and secreting soluble factors that rendered malignant cells more sensitive to the virus.22

We finally established the therapeutic efficacy in vivo of AdF512v1 on tumors made of SKOV3-luc cells mixed with WI-38 and HMEC-1 cells. The cells mix was implanted subcutaneous for the clear limitation of injecting the mix directly into the peritoneum. Once tumors reached 100 mm³ we treated mice with three intratumor administrations of AdF512v1, Ad-F512 or phosphate-buffered saline (PBS) (at days 0, 3, and 7). At the end of the experiment one of three mice treated with AdF512v1 was completely free of tumor and the other two showed greatly reduced tumor volumes compared to the group of mice treated with Ad-F512 or PBS. The differences between the AdF512v1-treated group and the other two groups were statistically significant (Figure 8c and Supplementary Figure S9).
DISCUSSION

According to Globocan data base more than 200,000 cases of ovarian cancer are diagnosed each year. It is estimated that more than 125,000 women with ovarian cancer die each year. The most important determination of survival seems to be disease stage at diagnosis. Only ~20% of women are diagnosed at an early stage, but in most of the cases the disease is detected at an advanced stage leading to a poor prognosis.\(^\text{2-3}\) Early disease stage has a 5-year survival rate of greater than 70%, but for those diagnosed with advanced disease stage, it is below 15%. Currently available methods prove quite unable to detect ovarian cancer at an early stage,\(^\text{4}\) therefore new therapeutic tools are urgently needed.

Here, we characterized a novel CRAd that has been designed to target the tumor-associated stromal cell compartment since its replication is driven by a promoter fragment of the stroma-associated gene SPARC. We showed here that this novel CRAd was therapeutically effective in a xenograft model of disseminated/metastatic human ovary cancer inducing a major growth inhibitory effect including the complete remission of the tumor in 50% of the cases. Mostly important, this novel CRAd was also capable of replicate \textit{ex vivo} in explants of fresh samples of primary human ovary cancer, obtained from patients that underwent or not neoadjuvant chemotherapy, and in ovary cancer metastases; but contrary to the wild-type virus it was almost unable to replicate in noncancerous ovary samples. This oncolytic virus was able to replicate \textit{ex vivo} and eliminate \textit{in vivo} tumors made of malignant and stromal cells.

Initial uses of oncolytic viruses for therapeutically targeting ovarian cancers involved the use of ONYX-15 an oncolytic virus with broad cancer spectrum and nonselective replication capacity.\(^\text{11}\) The limited success of these initial trials was attributed at least in part to the reduced infective capacity of type 5 adenoviruses that entered cells through CAR receptor.\(^\text{11}\) In a second study, a replicative-competent Edmonston B measles vaccine strain that infects cells through CD46 was administered to patients with recurrent ovarian cancer.\(^\text{25}\) Fourteen of the 21 patients exhibited stable disease and CA-125 levels were reduced by >30% in 5 of the 21 patients.\(^\text{25}\) A more recent trial in recurrent malignant gynecologic diseases including ovarian cancer has been published.\(^\text{12}\) This trial was based on an infectivity-enhanced-oncolytic adenovirus carrying E1A mutated in the Rb-binding site whose transcriptional regulation was under the control of the wild-type promoter and the viral fiber was pseudotyped with an RGD motive to enhance viral infectivity. The authors found no severe adverse effect, and although no partial or complete responses were observed after 1 month follow up, reduced CA-125 levels were observed in 7 of 21 patients.\(^\text{12}\)

AdF512v1 is an improved version of Ad-F512 that was shown to inhibit melanoma and pancreatic cancer growth in preclinical models.\(^\text{22}\) AdF512v1 was improved by (i) the incorporation of an insulator sequence upstream of the F512-SPARC promoter, (ii) the incorporation of a mutated form of E1A unable to bind pRb, and (iii) virus pseudotyping with a chimeric 5/3 that binds preferentially to type 3 adenoviral receptors. The decision to assess the therapeutic efficacy in ovarian cancer of AdF512v1 was due to the fact that SPARC is expressed mainly in stromal cells (fibroblasts and endothelial cells) in close contact with the forefront of the epithelial tumor mass.\(^\text{17,18}\) Interestingly, AdF512v1 was also able to replicate in ovarian cancer cells that express negligible SPARC levels. Silencing of SPARC expression in some epithelial ovarian cancer cells is mainly due to promoter methylation.\(^\text{17,23}\) As shown in previous studies, methylation of the internal promoter would not hinder the activity of the oncolytic virus provided the transcription factors that regulate SPARC promoter activity are still expressed in the target cells.\(^\text{21}\)

In addition to the use of a promoter active both in the malignant and in the stromal cell compartment we decided to pseudo-type the virus with a chimeric 5/3 fiber that retargets the virus to enter malignant cells through CD46, although recent evidence points to desmoglein as an additional receptor for type 3 adenoviral fiber.\(^\text{26}\) We observed that vectors expressing the 5/3 chimeric fiber exhibited at least 40% increased infectivity and lytic effect on ovary cancer cells compared to the virus expressing the type 5 fiber. This is consistent with previous evidence showing that the Ad5/3 chimera displays enhanced infectivity in ovary cancer cell lines and purified primary tumor cells (~10-fold).\(^\text{5,6,27,28}\) Recently, it was shown that a full serotype 3 CRAd was as useful as the 5/3 pseudotype virus.\(^\text{29}\)

Reduced binding of E1A to pRb and p300/CPB emerged as a strategy to limit adenoviral replication in normal cells.\(^\text{30}\) Therefore, we decided to mutate E1A to eliminate its capacity to bind to either of the two proteins or to both of them. Indeed, we observed that with the sole exception of sample 18, AdF512v1 was completely unable to replicate in normal human ovary explants, while the wild-type virus replicated both in malignant and normal ovary explants. In addition to the almost complete abrogation of its replication capacity in fresh human normal ovary samples AdF512v1 was also unable to replicate in the permissive Syrian hamster organs (data not shown). Thus, it appears that mutation in the pRB-binding site restricted AdF512v1 capacity to replicate in normal ovaries and greatly attenuated its potential harmful effect on normal organs. On the other hand, we observed that AdF512v1 exhibited an enhanced \textit{in vitro} activity even at the lowest MOI of 1 to 10 and \textit{ex vivo} activity in human ovary cancer explants. This enhanced lytic/replication capacity was in close coincidence with previous studies showing that CRAds carrying an E1A mutation in the pRB-binding site might exhibit similar or even better lytic effect \textit{in vitro} than CRAds carrying the E1Awt gene.\(^\text{30-32}\) It was hypothesized that in the absence of pRB-binding capacity, there is an augmented E1A transactivation function either because pRB sequestration no longer occurs due to the abrogation of E1A feedback inhibition, or a diminished E1A ubiquitination as a result of a decreased phosphorylation status.\(^\text{31}\)

Fresh cancer explants are being increasingly used as a reliable tool to assess viral capacity to replicate and lyse \textit{ex vivo} human samples that resemble the situation the virus might face in a clinical setting. This methodology has been already used in few works to assess the replication and lytic capacity of CRAds in breast and ovary explants.\(^\text{33-36}\) Besides, \textit{ex vivo} liver tissue slices were used to assess CRAd-mediated liver toxicity.\(^\text{6,33,37}\) However, we show for the first time that a CRAd such as AdF512v1 was also able to replicate in ovary cancer samples and metastatic tissue obtained from patients that underwent mainstay neoadjuvant chemotherapy that included paclitaxel and carboplatin to reduce the tumor.
pointed out that E4 levels in the tumor mass are underestimated with greater avidity compared to liver, spleen, and non-infiltrated AdF512v1 was retained at the tumor mass and infiltrated gonads and was extremely toxic to the liver in animal models. Moreover, as this serotype can infect at high levels lung, kidney, and prostate, these data demonstrate that adenovirus replication in the liver, spleens and gonads is less toxic than adenovirus type 5, indicating overall survival in ovary cancer. Ad-F512 was originally designed to target ovarian adenocarcinoma or nonmalignant ovary samples. The declaration of Helsinki protocols were followed and patients gave written informed consent. Samples were kept on ice in University of Wisconsin (UW) solution (ViaSpan; Barr Laboratories, Pomona, NY) until slicing or alternatively in RPMI medium (Invitrogen, Carlsbad, CA). Time from harvest to slicing was kept at an absolute minimum (<2 hours). The Krumdieck tissue slicing system (Alabama Research and Development, Birmingham, AL) was used in accordance with the manufacturer’s instructions and previously published techniques; in few cases samples were sliced manually. Viral infections were performed with a MOI of 500 in 500μl of 2% vol/vol FCS RPMI with 1% antibiotics, 1% L-glutamine into 24-well plates. Infections were allowed to proceed for 5 hours (E4 assay) or 24 hours (luciferase assay), and then the medium was removed and replaced with 10% vol/vol FCS RPMI.

Luciferase assays: Infected tissue slices were placed in cell culture lysis buffer (Promega, Madison, WI) with beads and homogenized with an ultra sonicator (Fisher Scientific Model 100, Pittsburgh, PA) at a setting of 15 watts for 10 seconds. The homogenate was centrifuged to pellet the debris, and luciferase activity was measured as described. Experiments were performed in triplicate. Protein concentration of the tissue homogenates was determined using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA) to allow normalization of luciferase expression.

Assessment of virus replication: DNA purification from infected tissue slices and qPCR for E4 was performed as described with slight differences since we selected 72 hours as the end of the experiment because we observed no decrease in explants viability up to 96 hours in culture (data not shown). Briefly, DNA was purified with the DNeasy Tissue kit (Qiagen, Santa Clarita, CA) or Genomic DNA extraction kit tissue (Real Genomics, RBC, Taiwan). The primers used for amplification of the E4 were forward E4Fub and reverse E4Rub (Supplementary Table S4) and detected with a E4 probe (Supplementary Table S4). Negative controls without template were performed for each reaction series, and an internal control (human β-actin) or total DNA were used to normalize the copy number for the E4 gene. Comparison of replication rates of different treatment groups were performed with a Student’s t-test.

In vitro cytotoxicity assay. For determination of virus-mediated cytotoxicity, 1 × 10⁴ cells were seeded in 24-well tissue culture plates and infected with the CRAds at indicated titers. After 6 days, cell viability was measured using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS assay; Promega).

Ex vivo replication of CRAds in tumors obtained from nude mice. Five to six-weeks-old female athymic N:NIH(S)-nu mice (obtained from Instituto
Leloir Facility or from the animal facility of the Faculty of Veterinary, University of La Plata, Argentina) were subcutaneous injected in one flank either with $3 \times 10^{10}$ SKOV3-luc cells or $4 \times 10^{4}$ PA-1 cells to produce an homogeneous ovary tumor or a mix of $3 \times 10^{6} + 4 \times 10^{5}$ SKOV3-luc or PA-1 cells respectively, mixed with $1 \times 10^{5}$ HMEC-1 and $1 \times 10^{6}$ WI-38 fibroblasts in 200μl of PBS to produce a heterogeneous tumors made of malignant and stromal cells. When the average tumor volume reached 500mm³, mice were sacrificed and the tumors were sliced and infected in vitro as described previously for patient samples.

**In vivo studies.** The i.p. tumors were established by injecting $3 \times 10^{6}$ SKOV3-luc cells/200μl into female nude mice ($n = 4–5$ /group). On day 7 when the tumor is already established (Supplementary Figure S10), $5 \times 10^{6}$ v.p. of Ad5F12v1 or vehicle were injected i.p. in 400μl of PBS. Imaging was performed before treatment on day -1 and then at days 9, 23, and 30 after adenovirus injection with anesthetized animals injected with 150μg/kg of D-luciferin i.p. After 10 minutes, the bioluminescent images were collected with a CCD, using the IVIS Imaging System (Xenogen, Alameda, CA), with the field of view set at 25-cm height. The photographic images used a 0.2-second exposure, 8 times, 2 binning (resolution), and open filter. The bioluminescent and gray-scale images were overlaid using LivingImage software (Xenogen). Regions of interest were drawn around the i. p tumors, and the total counts (photons) were summed in the entire tumor areas. None of the mice showed signs of wasting or other visible indications of toxicity and all animals under study received food and water ad-libitum. For studies on viral distribution, 5–6-weeks-old athymic N:NIH(S)-nu female mice were injected i.p. with $5 \times 10^{5}$ v.p./400μl of Ad5F12Luc (5/3). After 48 hours mice were sacrificed and livers, spleens, gonads, kidneys, lungs, stomachs, hearts, and intestines were harvested. Organ sections were used to evaluate the luciferase activity as we described for tumor samples. To establish viral clearance 5–6-weeks-old athymic N:NIH(S)-nu female mice were injected i.p. with $5 \times 10^{5}$ 500μl SKOV3-luc cells /200μl. Ten days later mice were injected once with Ad5F12v1 (5 $\times 10^{6}$ v.p./400μl); groups of 2–3 mice were sacrificed at the indicated times for tissue isolation. E4 levels were assessed as described above.

Five to six-weeks-old female nude mice were subcutaneous injected either with tumor cells alone or with a mix of tumor cells and stromal cells (SKOV3-luc (3 $\times 10^{5}$); WI-38 (10 $\times 10^{5}$); HMEC-1 (1 $\times 10^{5}$)). The in vivo treatment started when the average tumor volume reached 100mm³; mice were randomly separated in groups that received three intratumoral injections of $1 \times 10^{6}$ viral particles/mouse of either Ad5F12 or Ad5F12v1 on days 0, 3, and 7. Tumor volumes were estimated weekly from caliper measurements (volume = 0.5 × (width)$^2$ × length). Mice were sacrificed when tumors reached an average of 2,500mm³. None of the mice showed signs of wasting or other visible indications of toxicity.

**Ethics statement.** All experiments were approved by the Institutional Animal Care and Use Committee of the Fundación Instituto Leloir (Protocol #300P). The Fundación Instituto Leloir has an approved Animal Welfare Assurance as a foreign institution with the Office of Laboratory Animal Welfare, Number A5168-01.

**SPARC mRNA quantification.** Quantification was performed as previously described.

**SUPPLEMENTARY MATERIAL**

**Figure S1.** Flow cytometer analysis of ovary cancer cells after infection with Ad-wt or Ad5F12v1.

**Figure S2.** SPARC immunostaining and luciferase assay in patient samples.

**Figure S3.** Immunoprecipitation of E1A/host protein complexes.

**Figure S4.** In vivo bioluminescence assays following i.p. treatment.

**Figure S5.** In vivo bioluminescence assays following i.v. treatment.

**Figure S6.** Viability of stromal cells after infection with different viruses.

**Figure S7.** In vitro lysis of cells following previous infection with Ad5F12v1.

**Figure S8.** Ex vivo replication of Ad5F12v1 in tumor xenografts composed by malignant (PA-1) and stromal human cells.

**Figure S9.** Survival curve of mice-harboring subcutaneous tumors (malignant + stromal cells) treated with the different viruses or PBS.

**Figure S10.** Intraperitoneal tumor at day 7.

**Table S1.** Relative expression of SPARC mRNA levels in ovary cancer cell lines.

**Table S2.** Analysis of CRAd performance in human tissue slices.

**Table S3.** Luciferase expression of SKOV3-luc cells following co culture with stromal cells previously infected or not with Ad5F12v1.

**Table S4.** Specific primers used in this work.

**Materials and Methods.**

**ACKNOWLEDGMENTS**

This work was supported by grants from the National Agency for Promotion of Science and Technology (Anpcyt) Argentina, Fundación Bunge y Born, Argentina, the Programa Bicentenario-BancoMundial, Conicyt, Chile CTE-06 and grant number S550CA101955-07. We are indebted to the continuous support of Amigos de la Fundación Instituto Leloir para la Investigación en Cancer (AFULIC) Foundation, Argentina. We acknowledge the technical support of Florencia Straminsky and Cecilia Rotondaro from Fundación Instituto Leloir and Christine Dowralt from the Pathology Department at the University of Alabama at Birmingham, AL. This work was done in Ciudad Autónoma de Buenos Aires, Argentina and Birmingham, AL.

**REFERENCES**


© The American Society of Gene & Cell Therapy

**CRAd Activity in Human Ovarian Cancer Models**
© The American Society of Gene & Cell Therapy

CRAd Activity in Human Ovarian Cancer Models


